TY - JOUR
T1 - Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia
T2 - real-world data
AU - Badar, Talha
AU - Szabo, Aniko
AU - Litzow, Mark
AU - Burkart, Madelyn
AU - Yurkiewicz, Ilana
AU - Dinner, Shira
AU - Hefazi, Mehrdad
AU - Shallis, Rory M.
AU - Podoltsev, Nikolai
AU - Patel, Anand A.
AU - Curran, Emily
AU - Wadleigh, Martha
AU - Balasubramanian, Suresh
AU - Yang, Jay
AU - Arslan, Shukaib
AU - Aldoss, Ibrahim
AU - Mattison, Ryan
AU - Cenin, Danielle
AU - Siebenaller, Caitlin
AU - Advani, Anjali
AU - Liedtke, Michaela
AU - Atallah, Ehab
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/8
Y1 - 2021/8
N2 - Safety and efficacy of allogeneic hematopoietic stem cell transplantation (alloHCT) consolidation after blinatumomab is largely undetermined. To address this issue, we assembled multi-center data of relapsed refractory (RR) acute lymphocytic leukemia (ALL) patients who received alloHCT after blinatumomab. From December 2014 to May 2019, 223 patients who received blinatumomab for RR ALL outside clinical trials were identified. Among them, 106 (47%) patients transplanted post blinatumomab were evaluated for response and toxicity. Ninety-two (87%) patients received alloHCT after achieving CR, while remaining received subsequent salvage prior to undergoing alloHCT. Progression free survival (PFS) and overall survival (OS) at 2 years post alloHCT was 48% (95% CI: 36–59%) and 58% (95% CI: 45–69%), respectively. The cumulative incidence of GIII–IV aGVHD at 3 months was 9.9% (95% CI: 5.0–16.6%). Similarly, cumulative incidence of moderate to severe cGVHD at 2 years was 34.4% (95% CI: 23.7–45.3%). The overall survival at 2 years was not significantly different in patient who achieved CR with MRD negative (68.4% [95% CI: 28.5–89.1%]) compared to CR with MRD positive (63.4% [95% CI: 47.8–75.4%]) prior to alloHCT (p = 0.8). Our real-world analysis suggests that alloHCT is feasible and effective post blinatumomab in patients with RR ALL.
AB - Safety and efficacy of allogeneic hematopoietic stem cell transplantation (alloHCT) consolidation after blinatumomab is largely undetermined. To address this issue, we assembled multi-center data of relapsed refractory (RR) acute lymphocytic leukemia (ALL) patients who received alloHCT after blinatumomab. From December 2014 to May 2019, 223 patients who received blinatumomab for RR ALL outside clinical trials were identified. Among them, 106 (47%) patients transplanted post blinatumomab were evaluated for response and toxicity. Ninety-two (87%) patients received alloHCT after achieving CR, while remaining received subsequent salvage prior to undergoing alloHCT. Progression free survival (PFS) and overall survival (OS) at 2 years post alloHCT was 48% (95% CI: 36–59%) and 58% (95% CI: 45–69%), respectively. The cumulative incidence of GIII–IV aGVHD at 3 months was 9.9% (95% CI: 5.0–16.6%). Similarly, cumulative incidence of moderate to severe cGVHD at 2 years was 34.4% (95% CI: 23.7–45.3%). The overall survival at 2 years was not significantly different in patient who achieved CR with MRD negative (68.4% [95% CI: 28.5–89.1%]) compared to CR with MRD positive (63.4% [95% CI: 47.8–75.4%]) prior to alloHCT (p = 0.8). Our real-world analysis suggests that alloHCT is feasible and effective post blinatumomab in patients with RR ALL.
UR - http://www.scopus.com/inward/record.url?scp=85103674051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103674051&partnerID=8YFLogxK
U2 - 10.1038/s41409-021-01279-w
DO - 10.1038/s41409-021-01279-w
M3 - Article
C2 - 33824440
AN - SCOPUS:85103674051
SN - 0268-3369
VL - 56
SP - 1998
EP - 2004
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 8
ER -